Whereas the work of Badran et al. seems to confirm the efficacy of Infliximab administration to treat colitis in cancer patients under ICB therapy in agreement with a recent retrospective clinical study [2], the consequences of anti-TNF and ICB combination on other irAEs and putative suspected unexpected serious adverse reactions (SUSAR) warrants further investigation. Here, TNF is linked to colitis.